- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06962917
- Original Trial
Cross-Cultural Differences in the Network Structure of Social Anxiety and Body Dysmorphic Symptoms
April 29, 2025 updated by: Philipps University Marburg
Examining the Network Structure of Social Anxiety and Body Dysmorphic Symptoms in American, German, and Japanese: A Cross-Cultural Study
This study will examine cross-cultural differences in the network structure of social anxiety and body dysmorphic symptoms across Germany, the United States, and Japan.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study will investigate the network structure of social anxiety, body dysmorphic symptoms, depressive symptoms, and shame across Germany, the United States, and Japan.
Social anxiety disorder and body dysmorphic disorder frequently co-occur and share several clinical features beyond fear of negative evaluation (Coles et al., 2006; Dietel et al., 2021; Fang et al., 2011).
Both conditions have also been found to exhibit high comorbidity with major depressive disorder (Acarturk et al., 2008; Grant et al., 2005; Gunstad & Phillips, 2003; Phillips et al., 1998).
Cognitive-behavioral therapy targeting social anxiety disorder or body dysmorphic disorder has been shown to significantly alleviate depressive symptoms (e.g., Enander et al., 2016; Noda et al., 2023; Ritter et al., 2023).
Shame has also been implicated in the development of depressive symptoms, as well as social anxiety disorder and body dysmorphic disorder (Kim et al., 2011).
Comparing the symptom networks of social anxiety, body dysmorphic symptoms, and depression-and identifying central symptoms within each cultural context-may contribute to the development of transdiagnostic treatments with cross-cultural applicability.
Study Type
Observational
Enrollment (Actual)
1523
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hessen
-
Marburg, Hessen, Germany, 35032
- Department of Psychology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
German, American, and Japanese individuals
Description
Inclusion Criteria:
- German, American, and Japanese citizens over 18 years old.
Exclusion Criteria:
- Individuals who do not obtain consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
German, American, and Japanese citizens over 18 years old
|
This study is a cross-cultural study, not an intervention study.
A total of 1,523 participants (484 from Germany, 548 from the United States, and 491 from Japan) were recruited.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief version of Fear of Negative Evaluation scale
Time Frame: From March 2025 to April 2025
|
The Brief version of Fear of Negative Evaluation scale measures fear of negative evaluation.
The scale consists of 12 items, including eight for the straightforwardly worded items and four for the reverse worded items.
Each item is rated on a 5-point scale ranging from 1 (not characteristic of me) to 5 (extremely characteristic of me), with higher scores indicating greater fear of negative evaluation.
It is recommended that the straightforwardly worded items (8 items) are used for the assessment of fear of negative evaluation.
The total score, based on all 12 items, ranges from 12 to 60.
When using only the straightforwardly worded items, the total score ranges from 8 to 40.
|
From March 2025 to April 2025
|
|
Mini-Social Phobia Inventory
Time Frame: From March 2025 to April 2025
|
The Mini-social phobia inventory measures social anxiety and avoidance behavior.
The scale contains three items rated on a 5-point scale from 0 (not at all) to 4 (extremely), with higher scores indicating greater social anxiety symptoms.
The total score ranges from 0 to 12.
|
From March 2025 to April 2025
|
|
Appearance Anxiety Inventory.
Time Frame: From March 2025 to April 2025
|
The Appearance Anxiety Inventory measures symptoms of body dysmorphic disorder.
The scale contains ten items rated on a 5-point scale from 0 (not at all) to 4 (all the time), with higher scores indicating greater symptoms of body dysmorphic disorder.
The total score ranges from 0 to 40, with scores of 19 or above indicating caseness.
|
From March 2025 to April 2025
|
|
Patient Health Questionnaire-9
Time Frame: From March 2025 to April 2025
|
The Patient Health Questionnaire-9 assesses depressive symptoms.
It consists of nine items, each rated on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day), with higher scores indicating more severe depressive symptoms.
The total score ranges from 0 to 27.
|
From March 2025 to April 2025
|
|
External and Internal Shame Scale
Time Frame: From March 2025 to April 2025
|
The External and Internal Shame Scale measures external shame and internal shame.
It consists of eight items, each rated on a 5-point scale ranging from 0 (never) to 4 (always), with higher scores indicating greater levels of shame.
The total score ranges from 0 to 32.
|
From March 2025 to April 2025
|
|
Auckland individualism and collectivism scale
Time Frame: From March 2025 to April 2025
|
The Auckland individualism and collectivism scale measures individualism (competitiveness, uniqueness, and responsibility) and collectivism (advise and harmony).
The scale consists of 26 items, each rated on a 6-point scale ranging from 1 (never or almost never) to 6 (always), with higher scores indicating greater levels of the respective construct.
The total score ranges from 26 to 156.
|
From March 2025 to April 2025
|
|
Demographic data
Time Frame: From March 2025 to April 2025
|
Age, location, ethnicity, education history, sexual orientation, biological sex, Gender identity, etc.
|
From March 2025 to April 2025
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
LGBTQIA+ minority stress questionnaire
Time Frame: From March 2025 to April 2025
|
The LGBTQIA+ minority stress questionnaire measures level of stress of LGBTQIA+ minority.
The scale contains 19 items rated on a 5-point scale from 0 (strongly disagree) to 4 (strongly agree), with higher scores indicating greater level of stress of LGBTQIA+ minority.
The total score ranges from 0 to 76.
|
From March 2025 to April 2025
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2025
Primary Completion (Actual)
April 2, 2025
Study Completion (Actual)
April 2, 2025
Study Registration Dates
First Submitted
March 28, 2025
First Submitted That Met QC Criteria
April 29, 2025
First Posted (Actual)
May 8, 2025
Study Record Updates
Last Update Posted (Actual)
May 8, 2025
Last Update Submitted That Met QC Criteria
April 29, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025-01k-rev
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Bekelu Teka WorkuJimma UniversityNot yet recruitingPrenatal Depression | Mental Health Related Quality of Life | Maternal Postpartum Depression | Paternal Postpartum DepressionEthiopia
Clinical Trials on Cross sectional study
-
Istanbul University - Cerrahpasa (IUC)CompletedFall | Vertebral Fracture | Postmenopausal Osteoporosis | Fracture of VertebraTurkey
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Singapore National Eye CentreSingHealth Translational Immunology and Inflammation Centre; TTSH Eye ClinicCompletedDry Eye Syndrome | AutoimmunitySingapore
-
Singapore National Eye CentreSingapore General HospitalCompletedDry Eye | GVHDSingapore
-
University of CopenhagenRecruiting
-
Hossam Adly MohamedRecruitingPeripheral Vascular Diseases and Presentation in Patient With Autoimmune DiseasesEgypt
-
Centre de Recherche Médicale et SanitaireCompletedto Contribute to a Better Control of COVID-19 in Children in NigerNiger
-
CalydialCompletedHemodialysis | DIALYSIS SYMPTOMS AND ANXIETYFrance
-
University Hospital, GhentUniversity GhentCompletedOverweight and ObesityBelgium
-
Medical University of GrazRecruitingCovid19 | Stress | Bipolar DisorderAustria